Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).

Lin HM, Scheinberg T, Portman N, Kim RMN, Mellor R, Huynh K, Faulkner AN, Mellett NA, Davis ID, Martin A, Sullivan D, Joshua A, McJannett M, Subhash V, Yip S, Azad AA, Marschner IC, North SA, McDermott RS, Chi KN, Stockler MR, Sweeney CJ, Meikle PJ, Horvath LG

Open source

DOI: 10.1016/j.annonc.2025.05.529
Published: 2025 Sep
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2025.05.529,
  title = {Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).},
  author = {Lin HM and Scheinberg T and Portman N and Kim RMN and Mellor R and Huynh K and Faulkner AN and Mellett NA and Davis ID and Martin A and Sullivan D and Joshua A and McJannett M and Subhash V and Yip S and Azad AA and Marschner IC and North SA and McDermott RS and Chi KN and Stockler MR and Sweeney CJ and Meikle PJ and Horvath LG},
  year = {2025},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2025.05.529},
  url = {https://doi.org/10.1016/j.annonc.2025.05.529}
}

RIS

TY  - JOUR
TI  - Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).
AU  - Lin HM
AU  - Scheinberg T
AU  - Portman N
AU  - Kim RMN
AU  - Mellor R
AU  - Huynh K
AU  - Faulkner AN
AU  - Mellett NA
AU  - Davis ID
AU  - Martin A
AU  - Sullivan D
AU  - Joshua A
AU  - McJannett M
AU  - Subhash V
AU  - Yip S
AU  - Azad AA
AU  - Marschner IC
AU  - North SA
AU  - McDermott RS
AU  - Chi KN
AU  - Stockler MR
AU  - Sweeney CJ
AU  - Meikle PJ
AU  - Horvath LG
PY  - 2025
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2025.05.529
UR  - https://doi.org/10.1016/j.annonc.2025.05.529
ER  -

APA

HM, L., T, S., N, P., RMN, K., R, M., K, H., AN, F., NA, M., ID, D., A, M., D, S., A, J., M, M., V, S., S, Y., AA, A., IC, M., SA, N., RS, M., KN, C., MR, S., CJ, S., PJ, M., & LG, H. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2025.05.529

Source records

pubmed · retrieved 2026-09-27T10:15:34.182Z